BSE filing, NSE: BPLPHARMA. Summary written from the filing by ALFA Finder's alert engine.
Bharat Parenterals Ltd: key numbers
- Share price
- ₹2,320.40
- Market cap
- ₹1,599 Cr
- Revenue (annual)
- ₹345.4 Cr
- Net profit (annual)
- ₹-8.19 Cr
- P/E (TTM)
- 1285.8×Sector 49.0×
- Promoter holding
- 67.20%+0.00% QoQ
- FII holding
- 0.11%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Bharat Parenterals Ltd
All →Bharat Parenterals Earnings Call Transcript: Key Takeaways
Q2 FY27 consolidated revenue ₹136.3 Cr (+110% YoY, +45% QoQ) and PAT ₹11.8 Cr, the first group profit quarter, led by Innoxel. Standalone margins squeezed by input costs; FY27 guidance maintained.
Bharat Parenterals Investor Presentation: Key Takeaways
Q2 FY27 consolidated revenue ₹136.3 Cr (+110.9% YoY), EBITDA ₹23.6 Cr (17.3%), PAT ₹11.8 Cr; Innoxel turned profitable.
Bharat Parenterals Q2 FY27 Results: Turns Profitable, Net Profit ₹11.8 Cr
Bharat Parenterals approved unaudited standalone results for the quarter ended 30 September 2026. The company reported profit and revenue growth versus the prior-year quarter.
- Key figure
- Net profit ₹11.8 Cr
Bharat Parenterals Board Meeting Date
Bharat Parenterals will hold a board meeting on October 29, 2026 to consider unaudited standalone and consolidated results. Trading window has been closed since October 1, 2026.
Bharat Parenterals Annual General Meeting
Bharat Parenterals held an EGM via video conferencing on October 23, 2026. Members considered a preferential equity issue and Section 186 investment and guarantee limits.
Bharat Parenterals Business Update
Innoxel Lifesciences, a Bharat Parenterals subsidiary, began U.S. commercial supply of its first CMO product. This adds recurring manufacturing revenue to its existing licensing income.
Other price movement clarification announcements
All →Sigachi Industries Price Movement Clarification
Sigachi Industries responded to NSE's query on a significant volume spurt, stating it has disclosed all material information. The company attributes the movement to market conditions.
Narayana Hrudayalaya Price Movement Clarification
Narayana Hrudayalaya responded to a Bloomberg report that Aster DM is in talks to acquire northern India hospitals. The company said it does not comment on speculation and has no disclosable event.
Symbiox Investment & Trading Co Price Movement Clarification
Symbiox Investment & Trading Company responded to BSE's query on significant share price movement. It says no undisclosed material information exists and the move appears market-driven.
GHCL Textiles Price Movement Clarification
GHCL Textiles confirmed no specific reason for the volume spike, attributing it to market-driven activity. No pending Reg 30 disclosure exists.
Centenial Surgical Suture Price Movement Clarification
Centenial Surgical Suture reports an abnormal share price rise to BSE, alleging possible market manipulation. The company requests SEBI and BSE to investigate and take penal action.
Hubtown Price Movement Clarification
Hubtown Ltd responded to NSE's spurt-in-volume query, stating no price-sensitive information was withheld and management has no connection to the volume increase. No new information or event is disclosed.